Duobrii in Combination With Biologics

Purpose

12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks

Condition

  • Psoriasis

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Male or female adult ≥ 18 years of age; 2. Diagnosis of chronic plaque-type 3. Psoriasis affecting 2%-10% BSA 4. Patient is being treated with biologic therapy for a minimum of 24 weeks 5. Able and willing to give written informed consent prior to performance of any study-related procedures

Exclusion Criteria

  1. Psoriasis affecting ˂2% or >10% BSA 2. Patient not receiving a biologic agent, or receiving biologic agent <24weeks 3. Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit. 4. Has previously used DUOBRII

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Intervention Model Description
open label
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Open Label Duobrii 		Duobrii QD
  • Drug: Duobrii
    duobrii applied daily for 4 weeks followed by every other day for 4 weeks.

Recruiting Locations

Psoriasis Treatment Center of Central New Jersey
East Windsor 8354649, New Jersey 5101760 08520
Contact:
Elise Nelson
609-443-4500
enelson@windsordermatology.com

More Details

Status
Recruiting
Sponsor
Psoriasis Treatment Center of Central New Jersey

Study Contact

Jerry Bagel, MD
6094434500
dreamacres1@aol.com

Detailed Description

A single center, pilot study of 25 subjects to assess 12 weeks DUOBRII to patients with 2%-10% body surface area who are receiving biologic therapy for at least 24 weeks